The impact of hypothetical PErsonalised Risk Information on informed choice and intention to undergo Colorectal Cancer screening colonoscopy in Scotland (PERICCS)-a randomised controlled trial.
Colorectal cancer screening
Faecal immunochemical test
Informed choice
Personalised risk
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
20 10 2020
20 10 2020
Historique:
received:
08
05
2020
accepted:
17
08
2020
entrez:
20
10
2020
pubmed:
21
10
2020
medline:
13
2
2021
Statut:
epublish
Résumé
There is currently no existing evidence on the effects of personalised risk information on uptake of colonoscopy following first line screening for colorectal cancer. This study aimed to measure the impact of providing risk information based on faecal haemoglobin concentration to allow a fully informed choice around whether or not to undergo colonoscopy. Two thousand seven hundred sixty-seven participants from the Scottish Bowel Screening Programme (SBoSP) database, who had not recently been invited for screening, were randomised to receive one of three types of hypothetical risk information materials: (1) numerical risk information (risk categories of one in 40, one in 1600 and one in 3500), (2) categorical risk information (highest, moderate and lowest risk), or (3) positive screening result letter (control group). The primary outcome was the impact of the risk materials on intention to undergo colonoscopy, to allow comparison with the current colonoscopy uptake of 77% for those with a positive screening result in the SBoSP. Secondary outcomes were knowledge, attitudes and emotional responses to the materials. Four hundred thirty-four (15.7%) agreed to participate with 100 from the numerical risk group (69.0%), 104 from the categorical risk group (72.2%) and 104 from the control group (71.7%) returning completed materials. Intention to undergo colonoscopy was highest in the highest risk groups for the numerical and categorical study arms (96.8% and 95.3%, respectively), but even in the lowest risk groups was > 50% (58.1% and 60.7%, respectively). Adequate knowledge of colorectal screening and the risks and benefits of colonoscopy was found in ≥ 98% of participants in all three arms. All participants reported that they found the information easy-to-understand. 19.1%, 24.0% and 29.6% of those in the numerical, categorical and control group, respectively, reported that they found the information distressing (p > 0.05). Applying the risk categories to existing SBoSP data shows that if all participants were offered an informed choice to have colonoscopy, over two thirds of participants would intend to have the test. Equating to an increase in the number of screening colonoscopies from approx. 14,000 to 400,000 per annum, this would place an unmanageable demand on colonoscopy services, with a very small proportion of cancers and pre-cancers detected. However, the response to the materials were very positive, suggesting that providing risk information to those in lowest and moderate risk groups along with advice that colonoscopy is not currently recommended may be an option. Future research would be required to examine actual uptake. Date applied 1 December 2017 ISRCTN number 14254582 .
Sections du résumé
BACKGROUND
There is currently no existing evidence on the effects of personalised risk information on uptake of colonoscopy following first line screening for colorectal cancer. This study aimed to measure the impact of providing risk information based on faecal haemoglobin concentration to allow a fully informed choice around whether or not to undergo colonoscopy.
METHODS
Two thousand seven hundred sixty-seven participants from the Scottish Bowel Screening Programme (SBoSP) database, who had not recently been invited for screening, were randomised to receive one of three types of hypothetical risk information materials: (1) numerical risk information (risk categories of one in 40, one in 1600 and one in 3500), (2) categorical risk information (highest, moderate and lowest risk), or (3) positive screening result letter (control group). The primary outcome was the impact of the risk materials on intention to undergo colonoscopy, to allow comparison with the current colonoscopy uptake of 77% for those with a positive screening result in the SBoSP. Secondary outcomes were knowledge, attitudes and emotional responses to the materials.
RESULTS
Four hundred thirty-four (15.7%) agreed to participate with 100 from the numerical risk group (69.0%), 104 from the categorical risk group (72.2%) and 104 from the control group (71.7%) returning completed materials. Intention to undergo colonoscopy was highest in the highest risk groups for the numerical and categorical study arms (96.8% and 95.3%, respectively), but even in the lowest risk groups was > 50% (58.1% and 60.7%, respectively). Adequate knowledge of colorectal screening and the risks and benefits of colonoscopy was found in ≥ 98% of participants in all three arms. All participants reported that they found the information easy-to-understand. 19.1%, 24.0% and 29.6% of those in the numerical, categorical and control group, respectively, reported that they found the information distressing (p > 0.05).
CONCLUSIONS
Applying the risk categories to existing SBoSP data shows that if all participants were offered an informed choice to have colonoscopy, over two thirds of participants would intend to have the test. Equating to an increase in the number of screening colonoscopies from approx. 14,000 to 400,000 per annum, this would place an unmanageable demand on colonoscopy services, with a very small proportion of cancers and pre-cancers detected. However, the response to the materials were very positive, suggesting that providing risk information to those in lowest and moderate risk groups along with advice that colonoscopy is not currently recommended may be an option. Future research would be required to examine actual uptake.
TRIAL REGISTRATION
Date applied 1 December 2017 ISRCTN number 14254582 .
Identifiants
pubmed: 33076932
doi: 10.1186/s12916-020-01750-3
pii: 10.1186/s12916-020-01750-3
pmc: PMC7574531
doi:
Banques de données
ISRCTN
['ISRCTN14254582']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
285Subventions
Organisme : Chief Scientist Office
ID : HIPS/16/44
Pays : United Kingdom
Organisme : Chief Scientist Office, Scottish Government Health and Social Care Directorate
ID : HIPS/16/44
Pays : International
Références
Soc Sci Med. 2015 Oct;142:118-27
pubmed: 26301484
BMJ. 2019 Oct 2;367:l5515
pubmed: 31578196
Psychol Sci Public Interest. 2007 Nov;8(2):53-96
pubmed: 26161749
J Med Screen. 2008;15(2):76-82
pubmed: 18573775
Cochrane Database Syst Rev. 2013 Feb 28;(2):CD001865
pubmed: 23450534
BMJ. 2010 Oct 26;341:c5370
pubmed: 20978060
Br J Clin Psychol. 1992 Sep;31(3):301-6
pubmed: 1393159
Ann Intern Med. 2018 Oct 2;169(7):439-447
pubmed: 30242328
Ann Clin Biochem. 2019 Jul;56(4):472-479
pubmed: 31037954
Gut. 2020 Mar;69(3):523-530
pubmed: 31455608
Arch Intern Med. 2011 Apr 11;171(7):636-41
pubmed: 21149743
Clin Gastroenterol Hepatol. 2009 Jun;7(6):676-81.e1-3
pubmed: 19514116
United European Gastroenterol J. 2013 Jun;1(3):198-205
pubmed: 24917960
BMC Cancer. 2016 Feb 13;16:96
pubmed: 26872450
Yonsei Med J. 1991 Jun;32(2):131-8
pubmed: 1949916
J Clin Pathol. 2013 May;66(5):415-9
pubmed: 23418340
BMC Public Health. 2019 Apr 16;19(1):411
pubmed: 30991987
Patient Educ Couns. 2003 Jul;50(3):247-53
pubmed: 12900094
Patient Educ Couns. 2020 Feb;103(2):359-368
pubmed: 31451360
Br J Clin Psychol. 1983 Nov;22 (Pt 4):245-9
pubmed: 6640176
Cochrane Database Syst Rev. 2007 Apr 18;(2):MR000008
pubmed: 17443629
Aust J Gen Pract. 2018 Mar;47(3):139-145
pubmed: 29621846
Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1485-91
pubmed: 17627015
Health Expect. 2001 Jun;4(2):99-108
pubmed: 11359540